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The concept that patients with only a few metastases from 
a malignant tumor can potentially be cured was developed 
in 1995 and termed “Oligo” (few) metastasis, describing 
an intermediate stage between localized and metastasized 
cancer (1). This concept is based on the hypothesis that 
there is a distinct stage of limited metastatic capability 
of the primary tumor (2): metastatic spread that behaves 
hierarchical in time and number opens the therapeutic 
window for a cure at an early, an “oligometastatic” stage. 
Based on this concept, physicians have started treating 
these patients with locally ablative therapies in a curative 
intention. For instance, resection of colorectal liver 
metastases has led to long-term survival of patients (3). 
Similarly for non-small cell lung cancer (NSCLC), data 
suggests that long-term survival may be achieved for a subset 
of oligometastatic patients if treated radically (4). However, 
details of treatment concepts vary widely and only few 
studies have prospectively investigated the optimal treatment 
strategies for such patients. For instance, the definition of 
how many metastases are in fact “oligo—a few” remains 
controversial. Illustrating this point, 20 clinical studies 
examined by Reyes and Pienta on oligometastatic lung cancer 
used 17 different definitions and each study performed a 
different treatment pattern (5). Nevertheless, according to a 
survey conducted among over 1,000 radiation oncologists in 
over 40 countries in 2017, a large majority (83%) is treating 
patients in an oligometastatic setting with stereotactic body 
radiation therapy (SBRT), also referred to as stereotactic 
ablative radiotherapy (SABR) and 59% of the remaining 
physicians plan to implement this treatment soon (6). 
In the following, we will illustrate the current status 
of oligometastasis and future strategies from different 
perspectives.
Guidelines perspective
In NSCLC, the oligometastatic stage has been implemented 
into the 8th TNM-system (7), as well as the National 
Comprehensive Cancer Network (NCCN) guidelines 
(NCCN 3, 2017). Stage IVa M1b is defined as a single 
extrathoracic metastasis, where local treatment with 
radiotherapy or surgical resection is recommended. The 
ESMO guideline gives a less strong recommendation: 
For patients with one to three synchronous metastases, 
inclusion of patients into clinical trials for locally ablative 
treatment is recommended due to lack of high-level 
evidence. The exception is a solitary brain metastasis, 
for which stereotactic radiosurgery (SRS) or resection is 
recommended. In patients with activating driver mutations, 
only a level IVB recommendation is given for SBRT in the 
oligometastatic setting, because only retrospective data is 
currently available (8,9).
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Prospective clinical trials
Despite being recommended in guidelines, the evidence for 
a patient benefit from local treatment in an oligometastatic 
stage is low and based on few studies.
Level I evidence for a survival benefit of locally ablative 
treatment exists for limited brain metastases: Andrews and 
colleagues published the results of the RTOG9508 phase 
III randomized controlled trial (RCT) in 2004 in which the 
group investigated the effect of adding a stereotactic boost 
to whole brain radiotherapy in patients with three or fewer 
brain metastases from any primary tumor. For patients with 
a single metastasis, a median overall survival (OS) benefit of 
1.6 months was reported (10).
For unresectable colorectal hepatic metastases, a 
randomized phase II study (CLOCC-trial) evaluated OS 
for 119 patients without extrahepatic disease comparing 
systemic treatment alone with systemic treatment plus locally 
ablative treatment using radio-frequency ablation (11). In 
2017, the long-term follow-up data were published showing 
a statistically significant OS benefit (HR 0.58, P=0.01) at 
almost 10 years follow-up for patients in the experimental 
arm. The OS-rate at 8 years was 35.9% vs. 8.9% for the 
combined therapy arm and the systemic treatment only arm, 
respectively (12). 
For  o l igometastat ic  NSCLC, two prospect ive 
randomized studies are available: Gomez and colleagues 
have conducted a phase II RCT investigating the effect 
of local consolidation therapy after first line systemic 
treatment of oligometastatic (three or fewer lesions) 
NSCLC on progression free survival (PFS). The study was 
terminated early, because the group of 25 patients receiving 
locally consolidative treatment showed a much better PFS 
compared to the 24 patients treated with maintenance 
systemic treatment, only (11.9 vs. 3.9 months). Importantly, 
systemic progression was delayed in patients that received 
locally consolidative treatment suggesting that the benefit of 
such local treatment may reach beyond the local treatment 
site. The local consolidative therapy included surgery, 
radiotherapy, or both. Radiotherapy was the preferred 
treatment regimen: 96% of patients randomized in the local 
intervention arm received some form of radiotherapy, 48% 
received SBRT. Notably, no grade 4 or 5 toxicities were 
reported (13). 
Iyengar and colleagues conducted a single institution 
phase II RCT comparing the PFS of NSCLC stage IV 
(up to five metastases) patients treated either with ablative 
radiotherapy followed by maintenance chemotherapy 
or with maintenance chemotherapy only. Of note, the 
authors defined the oligometastatic setting based on 
imaging performed after induction chemotherapy. All 
patients received maintenance chemotherapy either alone 
or in combination with SBRT. Furthermore, the authors 
excluded all patients, whose tumors harbored targetable 
mutations (Gomez et al. included such patients). This trial 
was small (n=29) as well and was likewise stopped early due 
to favorable results in the group treated with both, ablative 
radiotherapy and systemic treatment (9.7 vs. 3.5 months 
PFS, P=0.01). Toxicities were comparable in both groups 
and no in-field failures were observed in the group treated 
with ablative radiotherapy (14).
In summary, these two small prospective trials appear 
similar from a design perspective but large differences exist: 
Gomez et al. defined oligometastatic disease before first-
line systemic treatment, whereas Iyengar et al. defined 
oligometastatic disease after first-line systemic treatment. 
The type of local therapy differed as well: While Iyengar 
et al. exclusively treated locally with SBRT, the Gomez 
study allowed all combinations of radiotherapy and surgery. 
Furthermore, Gomez et al. included patients with targetable 
tumor mutations, whereas Iyengar et al. excluded those. 
Gomez et al. included three and fewer metastases and 
Iyengar et al. included five and fewer.
Overall, evidence of a benefit of locally ablative 
treatments—especially SBRT—in the oligometastatic setting 
for NSCLC patients is evolving, however, randomized 
phase III trials are yet to be conducted. The current lack of 
evidence-based recommendations for patient selection and 
optimal combination of local and systemic treatment options 
is considered a relevant risk and marks a concern for broad 
clinical implementation.
Overview of clinical trials evaluating the local 
treatment component
Several prospective clinical trials are currently recruiting, 
which address  dif ferent quest ions in the f ield of 
oligometastatic disease summarized in Table 1.
The STOP-NSCLC trial and the SABR-COMET-
trial focus on treatment of oligoprogressive disease after 
systemic therapy for NSCLC compared to standard of care 
(SOC) treatment. The CORE-trial additionally investigates 
breast and prostate cancer in the oligoprogressive setting. 
The STOMP-trial and NCT002-trial pursue similar 
questions for prostate and breast cancer, respectively. In 
contrast, the SARON-trial is investigating the role of 
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locally ablative treatments in the primary setting enrolling 
patients that have not received any tumor-therapy. The 
SABR-SCAN-trial aims to determine the optimal time for 
ablative treatment of pulmonary metastases from colorectal 
cancer (CRC) regarding PFS and patterns of progression 
comparing immediate with delayed treatment. The HALT-
trial focuses on the role of local treatment for NSCLC 
patients with tumors that harbor a mutation targetable by 
a tyrosine-kinase-inhibitor (TKI) in the oligoprogressive 
setting. And finally, the SABR for oligometastases trial 
(NCT02933242) is enrolling patients with all tumor types 
focusing on the toxicity induced by such treatment and the 
quality of life (QoL) for patients receiving SABR. 
Locally ablative treatment from a systemic 
perspective
As more patients are diagnosed with oligometastatic disease 
due to better imaging, loser definition of the term in 
general as well as longer survival, the correct identification 
of true oligometastatic disease is crucial. Biomarkers that 
avoid mistaking oligometastasis for systematic disease that 
was merely captured by imaging at a state of few metastases 
are urgently needed. 
However, studies analyzing the molecular basis for 
oligometastasis are scarce: Lussier and colleagues analyzed 
miRNAs from resected pulmonary metastases of 63 patients 
with ≤5 pulmonary metastases and developed a rate-of-
progression profile predicting the velocity of metastatic 
spread. The authors concluded that poly-metastasis that was 
captured at a state of few metastases and true oligometastasis 
are distinct entities on a molecular level (17).
Wong et al. analyzed miRNA from 17 primary tumors 
of any histology from patients with stage IV disease 
with five or fewer metastases treated within the group’s 
SBRT dose escalation study. They compared differential 
miRNA expression of patients that survived for more 
than 3 years to those who did not and developed a score 
Table 1 Selection of currently recruiting prospective clinical trials on oligometastasis
Name/type Primary Intervention Prior treatment Endpoint # of met
Status/expected 
completion
STOP-NSCLC RCT II NSCLC 1:2 SOC vs. SBRT to all 
oligo-progressive lesions 
CHT ≤6 weeks 
prior
PFS ≤5 Recruiting/04/2020
SABR-COMET (15) 
RCT II
NSCLC 1:2 SOC vs. SOC + SABR 
to all sites
CHT ≥4 weeks 
prior
OS ≤5 Active, not 
recruiting/11/2020
SARON-trial RCT III NSCLC Platinum-based 
doublet CHT vs. SOC + 
conventional RT + SABR
None OS ≤3 Recruiting/08/2022
HALT-trial RCT II/III NSCLC 2:1 continued TKI + SBRT 
vs. continued TKI only
TKI PFS ≤3 Recruiting/03/2021
SABR for 
oligometastases 
non-randomized II
Any SABR to all sites for all 
patients
CHT ≥2 days 
prior
Tox, QoL ≤5 Recruiting/10/2022
STOMP-trial (16) 
RCT II
Prostate 1:1 active surveillance vs. 
surgery/SBRT
Surgery/RT or 
both
ADT-free 
survival
≤3 Ongoing/05/2017
CORE-trial
RCT II/III
NSCLC, 
prostate, breast
1:1 SOC vs. SOC + SBRT CHT ≥4–6 months 
prior
PFS ≤3 Recruiting/10/2021
NRG BR002-trial 
RCT II/III
Breast 1:1 SOC vs. SOC + SBRT 
or surgery
≤6 months first 
line CHT
PFS + OS ≤2 Recruiting/12/2022
SABR-SCAN-trial 
RCT II
CRC 1:1 immediate vs. delayed 
SABR of pulmonary 
metastases
No prior RT 
allowed
PFS ≤3 Recruiting/06/2019
#, number. NSCLC, non-small cell lung cancer; RCT, randomized controlled trial; SOC, standard of care; SBRT, stereotactic body radiation 
therapy; PFS, progression free survival; OS, overall survival; SABR, stereotactic ablative radiotherapy; CRC, colorectal cancer; TKI, 
tyrosine-kinase-inhibitor.
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for predicting survival time (18). The validation of this 
score is ongoing.
Gundem and colleagues proposed an evolution of 
metastases analyzing the genetic makeup of multiple 
metastases of ten prostate cancer patients (19). They found 
that a metastasis-to-metastasis spread seems common. This 
finding might account for the delay in systemic spread after 
locally ablative treatments mentioned above and should be 
further investigated to elucidate the biological rationale for 
treatment of oligometastasis. 
Future applications perspective: SBRT and 
immunotherapy
The randomized phase III PACIFIC-trial recently showed 
an impressive gain of 11.2 months median PFS for stage 
III NSCLC patients receiving durvalumab, a PDL-1-
antibody, as maintenance therapy after radiochemotherapy 
compared to placebo (20). Considering that these patients 
received radiotherapy within 42 days of randomization, this 
trial raises the question whether SBRT of oligometastasis 
combined with adjuvant immunotherapy might impact the 
survival benefit more drastically than previously imagined. 
Furthermore, it gives rise to the hypothesis that the reported 
PFS benefit of stage III patients might be extrapolated to 
oligometastatic stage IV patients that receive additional 
locally ablative treatments. Building on this premise, a phase 
II trial (SABR-PDL1) is currently recruiting patients with 
metastatic CRC, NSCLC or renal cell carcinoma (RCC) for 
a single arm study investigating the effects of atezolizumab (a 
PDL-1-antibody) combined with SABR to all but one lesion 
on PFS. Results are expected in 2020.
Perspective of opportunity: register studies
One possible solution to advance the heterogeneous field 
of oligometastasis are register trials. The above-mentioned 
guidelines have led to increasingly utilized locally ablative 
treatments of oligometastasis. The accumulating clinical 
data could be used to draw conclusions for safe and 
beneficial implementation of these guidelines. Register 
studies will assess patterns of care and outcome for patients 
and may bridge the gap between guidelines and lack of 
current evidence.
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